Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Immunoallergology Unit, Careggi University Hospital, Florence, Italy.
J Asthma. 2024 Jan;61(1):72-75. doi: 10.1080/02770903.2023.2241910. Epub 2023 Aug 24.
Asthma is a chronic inflammatory disease that can lead to airways remodeling. Despite their well-known side-effects, oral corticosteroids (OCS) continue to be used to reduce exacerbations and control asthma symptoms in many patients.
We describe two cases of uncontrolled severe asthma characterized by systemic clinical consequences of prolonged OCS use, such as diabetes, weight gain, and osteoporosis.
Both patients were treated with Dupilumab. During follow-up both patients showed an improvement in asthma control and were able to gradually taper the OCS dose, thus reducing the clinical burden associated with hypercortisolism.
Dupilumab was able to control both the inflammatory-induced "airway remodeling" as well as the OCS-induced "patient remodeling".
哮喘是一种慢性炎症性疾病，可导致气道重塑。尽管口服皮质类固醇（OCS）有众所周知的副作用，但在许多患者中，仍继续使用 OCS 来减少恶化并控制哮喘症状。
我们描述了两例未经控制的严重哮喘病例，其特点是长期使用 OCS 引起的全身临床后果，如糖尿病、体重增加和骨质疏松症。
两名患者均接受了度普利尤单抗治疗。在随访期间，两名患者的哮喘控制均得到改善，并能够逐渐减少 OCS 剂量，从而减轻与皮质醇过多相关的临床负担。
度普利尤单抗能够控制炎症引起的“气道重塑”和 OCS 引起的“患者重塑”。
